معرفی
Xiaobing Shi is a Professor in the Department of Epigenetics at Van Andel Institute. His research focuses on understanding how histone modifications regulate chromatin dynamics and cancer pathogenesis, with a particular emphasis on identifying novel epigenetic readers and their roles in oncogenesis. Dr. Shi earned a B.S. from Wuhan University and a Ph.D. from the Chinese Academy of Sciences, followed by postdoctoral training at Stanford University. He previously held roles at the University of Texas MD Anderson Cancer Center.
- Education: B.S., Wuhan University; Ph.D., Chinese Academy of Sciences
- Postdoctoral Training: Stanford University (Kornberg and Gozani labs)
- Research Focus: Histone acetylation/methylation, transcription regulation, cancer epigenetics
His team investigates how dysregulated histone modification homeostasis contributes to cancer, with recent work identifying ENL and other readers as therapeutic targets. Key findings include linking histone acetylation to oncogenic gene expression in AML and discovering ENL degraders for leukemia treatment.
- Awards: Leukemia & Lymphoma Society Career Development Award, American Cancer Society Research Scholar Award, Kimmel Scholar Award
Dr. Shi mentors a team including Research Scientists Mengying Huang, Hongkuan Wang, Longxia Xu, Hongwen Xuan, and Yucong Yu. His lab collaborates on clinical trials targeting epigenetic mechanisms in cancers and Parkinson’s disease. Recent publications highlight advancements in histone reader inhibitors and chromatin regulation.
